Spruce Biosciences, Inc. (SPRB)

NCM – Real Time Price. Currency in USD

55.11

+2.34 (4.43%)

At close: Jun 26, 2026, 4:00 PM EDT

55.11

-0.00 (-0.00%)

After-hours: Jun 26, 2026, 4:31 PM EDT

15.06.2026

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta, CPA, as Vice President, Finance and Corporate Controller.“We are delighted to welcome both Eric and Tina, two accomplished leaders with deep biotech experie.

08.06.2026

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme replacement therapy (TA-ERT) in patients with Sanfilippo Syndrome Type B (MPS IIIB) were presented at the 18th International MPS & Related Lysosomal Disease.

28.05.2026

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 18th International MPS & Related Lysosomal.

27.05.2026

Spruce Biosciences to Participate in Upcoming Conferences in June

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in June. Jefferies Global Healthcare Conference Date and Time: June 4, 2026, at 11:05 a.m. ET Format: Presenta.

13.05.2026

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2026 and provided corporate updates. “We are very pleased with the meaningful progress we continue to make in advancing TA-ERT toward our planned biologics license application subm.

04.05.2026

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations. Mr. Walls brings more than 20 years of biopharmaceutical commercial leadership experience and has contribu.

21.04.2026

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the pricing of its previously announced underwritten public offering of 1,150,000 shares of its common stock at a price to the public of $50.00 per share and, in lieu of shares of common stock to a certain invest.

Videos

No Data

There is no data to display

Press releases

15.06.2026

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

08.06.2026

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme replacement therapy (TA-ERT) in patients with Sanfilippo Syndrome Type B (MPS IIIB) were presented at the 18th International MPS & Related Lysosomal Disease.

28.05.2026

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 18th International MPS & Related Lysosomal.

13.05.2026

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2026 and provided corporate updates. “We are very pleased with the meaningful progress we continue to make in advancing TA-ERT toward our planned biologics license application subm.

Spruce Biosciences, Inc. (SPRB)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences to Participate in Upcoming Conferences in June

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences to Participate in Upcoming Conferences in June

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Search stocks

Spruce Biosciences, Inc. (SPRB)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences to Participate in Upcoming Conferences in June

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences to Participate in Upcoming Conferences in June

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates